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Abstract
Background
Combination antiretroviral therapy (cART) is associated with marked immune reconstitution.
Although a long term viral suppression is achievable, not all children however, attain com-
plete immunological recovery due to persistent immune activation. We use CD4/CD8 ratio
like a marker of immune reconstitution.
Methods
Perinatal HIV-infected children who underwent a first-line cART, achieved viral suppression
in the first year and maintained it for more than 5 years, with no viral rebound were included.
Logistic models were applied to estimate the prognostic factors, clinical characteristics at
cART start, of a lower CD4/CD8 ratio at the last visit.
Results
146 HIV-infected children were included: 77% Caucasian, 45% male and 28% CDC C.
Median age at cART initiation was 2.3 years (IQR: 0.5–6.2). 42 (30%) children received
mono-dual therapy previously to cART. Time of undetectable viral load was 9.5 years (IQR:
7.8, 12.5). 33% of the children not achieved CD4/CD8 ratio >1. Univariate analysis showed
an association between CD4/CD8 <1 with lower CD4 nadir and baseline CD4; older age at
diagnosis and at cART initiation; and a previous exposure to mono-dual therapy. Multivari-
ate analysis also revealed relationship between CD4/CD8 <1 and lower CD4 nadir (OR:
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1.002, CI 95% 1.000–1.004) as well as previous exposure to mono-dual therapy (OR: 0.16,
CI 95% 0.003–0.720).
Conclusions
CD4/CD8 >1 was not achieved in 33% of the children. Lower CD4 nadir and previous expo-
sure to suboptimal therapy, before initiating cART, are factors showing independently asso-
ciation with a worse immune recovery (CD4/CD8 < 1).
Introduction
The combination antiretroviral therapy (cART) has led not only to a decrease in HIV viral
load but also to the recovery of CD4 T cell count and ultimately to the clinical improvement of
HIV-infected children [1, 2]. Plasma viremia suppression by cART is generally associated with
improvements in the immunological condition of patients, but some children fail to achieve
normalization of CD4 T cell count. [3]
Various mechanisms such as immune activation, on-going HIV replication and deficient
thymus output are associated with impaired immunological response to treatment in adults.
[4] In vertically HIV-1 infected children, the infection is acquired when the immune system is
still immature and the thymus is activated to produce new naïve T cells. [2] Highly active thy-
mus in early childhood may contribute to a better immune reconstitution if ART is initiated
early in life. [5] With the increase in age, the recovery through the naïve pool is progressively
damaging, hence early treatment is the key for immune reconstitution. [6] However, other
studies suggest that the recovery of the thymic function is age-independent and it is related to
peripheral CD4 cell depletion as well as HIV-1 suppression. [7]
Little is known about long term immune recovery in HIV-infected children on cART.
Immune recovery has been associated with earlier age, higher CD4 cell count and CD4 nadir
at cART initiation, whereas, severe immunosuppression is associated with an impaired CD4
recovery.[8, 9, 10, 11] cART significantly reduces the degree of immune activation and detect-
able viral load aggravates immune senescence in children. [12, 13]
Restoration of CD4/CD8 ratio requires both CD4 cell recovery and normalization of the
CD8 count. CD4/CD8 ratio has been associated with T cell activation, despite long term viral
suppression in both, children and adults, as well as evidence to support that this imbalance has
clinical importance in children. [14, 15, 16] A persistently low CD4/CD8 ratio despite viral
control reflects a higher risk of morbidity in HIV-infected adults. [17] In addition, CD4/CD8
ratio has been described as a predictor of CD4 response in HIV-1-infected adults. [18] So we
used CD4/CD8 ratio as a better predictor of long term immune recovery, since CD4 does not
predict immune activation.
The aim of this study was to study possible risk factors of not achieving a CD4/CD8 >1 in
children with long term immune reconstitution and maintained undetectable viral load, in
order to determine possible risk factors that could affect the immunological response to cART.
Materials and methods
Study design
IRB (Hospital de Getafe) approved the study. This is a multicenter observational study, within
the Pediatric branch of the National AIDS Research Network of Spain (CoRISpe). 383
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perinatal HIV-infected children were in follow up in this cohort when the study was con-
ducted. We included children who met the following inclusion criteria: 1) were receiving
cART when the study was conducted; 2) who underwent first-line cART, had evidence of viro-
logical suppression within the first year after cART initiation; 3) had subsequent maintenance
for more than 5 years with no viral rebound longer than 3 months at each time or at least until
last observation before transition to adult units. 146 children were analyzed. The study was
conducted from 1997 to December 2015.
Data were retrospectively collected from clinical visits performed every 3 months since
cART initiation. A duly signed informed consent was obtained from the parents or legal
guardians of patients <12 years and direct informed assent from patients aged�12 years in
order to participate in CoRISpe.
Definitions
First-line cART refers to those patients that had not taken any cART regimen previously, but
could have taken mono or dual antiretroviral therapy. Viral suppression was defined as<400
HIV-RNA copies/ml.
Patients with a CD4/CD8 ratio >1 at last clinical visit, were considered to have achieved
immune recovery and patients with a CD4/CD8 < 1 were considered not to reach immune
recovery. We studied possible risk factors at baseline of not achieving a CD4/CD8 >1 at last
visit, comparing both groups.
We considered baseline time when children started first line of cART.
Statistics
All continuous variables were expressed as median (IQR), and categorical variables as fre-
quency of distribution and rates. Differences between categorical variables were analysed
using the Chi square test and Fisher exact test. T student test was used to compare continuous
variables. A multivariable logistic regression model was used to analyse the relationship
between immune recovery and variables showing statistical significance in univariate analysis.
Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, NY: IBM
Corp). A P value of 0.05 was considered statistically significant.
Results
Clinical characteristics at baseline
A total of 146 HIV-infected children were enrolled in this study. Results are shown in Table 1.
In general, 81 (55%) were female and 47 (33%) were non Caucasian. Their median age at diag-
nosis was 0.6 years (IQR: 0.2, 2.1), the median age at cART initiation was 2.3 years (IQR: 0.5,
6.2) and 19 (28%) were on CDC stage C. Mono-dual therapy was taken by 42 (30%) patients
previous to cART, the rest of patients were naïve. The median of CD4 nadir was 457 cells/mm3
(IQR: 269, 678) and the median of CD4 cells and CD4% at baseline were 901 (IQR: 470, 1800)
cells/mm3 and 26% (IQR: 16, 35), respectively. The median CD4/CD8 ratio at baseline was 0.6
(IQR: 0.3, 1.2).
Follow up and immune recovery
As shown in Table 1, the median follow up period of patients in this study was more than 10
years, with a median duration of cART of 9.8 years (IQR: 8.1, 13.2) and a median of 2 different
cART regimens taken per patient (IQR: 2, 4). The patients remained with undetectable viral
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load for 9.5 years (IQR: 7.8, 12.5). 63 of 146 children (43%) had a viral blip in the follow up.
Median age at last observation was 14.4 years (IQR: 10.6, 18.1).
In general, the median CD4 count and percentage at last visit were 878 cells/mm3 (IQR:
672, 1085) and 38% (IQR: 33, 43), respectively, and the median CD4 /CD8 ratio was 1.2 (IQR:
0.9, 1.6).
Factors associated with not immune recovery
At last clinical visit, immune recovery (CD4/CD8 ratio >1) was not achieved in 48/146 (33%)
children. Results are shown in Table 2.
When comparing both groups of patients, the significant predictors of not immune recov-
ery by univariate analyses were lower CD4 nadir, lower CD4 count and percentage, lower
CD4/CD8 ratio and higher CD8 percentage at baseline.
An older age at HIV diagnosis and cART initiation was also associated to a unsuccessful
immune response. Being exposed to mono-dual therapy was also a predictor for worse
immune recovery.
Table 1. Baseline clinical characteristics of subjects.
Characteristics Total
N 146
Female gender, n (%) 81 (55%)
Age at diagnosis (years), median (IQR) 0.6 (0.2, 2.1)
Age at HAART initiation, median (IQR) 2.3 (0.5, 6.2)
Age at the last visit, median (IQR) 14.4 (10.6, 18.1)
Ethnicity, n (%)
Caucasian 97 (67%)
Non Caucasian 47 (33%)
Clinical stage at baseline, n (%)
N/A 78 (53.5%)
B 40 (27.5%)
C 19 (28%)
Nadir CD4 (cells/mm3), median (IQR) 457 (269, 678)
Nadir CD4%, median (IQR) 19 (11, 25)
Prior history of ART, n (%)
Mono or dual ART 42 (30%)
Naïve 104 (70%)
cART
Total n˚ of ART regimens, median (IQR) 3 (2, 5)
Total n˚ of cART regimens, median (IQR) 2 (2, 4)
Duration of cART (years), median (IQR) 9.8 (8.1, 13.2)
Baseline CD4 and CD8
CD4 (cells/mm3) at baseline, median (IQR) 901 (470, 1800)
CD4% at baseline, median (IQR) 26 (16, 35)
CD8 (cells/mm3) at baseline, median (IQR) 1398 (861, 1964)
CD8% at baseline, median (IQR) 37 (28, 40.5)
CD4/CD8 ratio at baseline, median (IQR) 0.6 (0.3, 1.2)
Viral load
Viral load at baseline (log10), median (IQR) 4.88 (4.12, 5.67)
Time of undetectable viral load, median (IQR) 9.5 (7.8, 12.5)
https://doi.org/10.1371/journal.pone.0220552.t001
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In multivariate analysis, a CD4/CD8 ratio < 1 was associated with lower CD4 nadir, (OR:
1.002, CI 95% 1.000–1.004) as well as previous exposure to mono-dual therapy (OR: 0.16, CI
95% 0.003–0.720).
Discussion
This study described the immune response in HIV-infected children treated with long term
cART, and reported an independent association between the lower CD4 nadir of patients and
the exposure to suboptimal ART regimens with a CD4/CD8 ratio <1, which represents a
unsuccessful immune recovery.
CD4/CD8 > 1 was not achieved in our study in 33% of the patients. Although the majority
of the studies in children define immune recovery as a CD4 percentage greater than 25% [19,
20], we used CD4/CD8 ratio as a better predictor of long term immune recovery, since CD4
does not predict immune activation. Recently, the CD4/CD8 ratio has been described as a
marker of immune activation in virologically suppressed HIV adults and children patients.
Table 2. Prognostic factors of subjects by immune recovery.
Univariate analysis Multivariate analysis
Characteristics Non Immune recovery
CD4 /CD8 < 1
Immune recovery
CD4/CD8 > 1
p Adjusted difference
Odds ratio (95% CI)
p
N 48 98 -
Female gender, n (%) 26 (32) 55 (68) 0,8
Age at diagnosis (years), median (IQR) 1.4 (0.2, 3.6) 0.5 (0.1–1.8) 0.03 0.957 (0.745–1.231) 0.7
Age at HAART initiation, median (IQR) 5.6 (2.1, 8.06) 1.3 (0.3, 4.4) < 0.001 0.951 (0.789–1.147) 0.6
Age at the last visit, median (IQR) 16.8 (13.4, 18.7) 13.5 (10.1. 17.8) 0.01
Ethnicity, n (%)
Caucasian 33 64 0.7
Non Caucasian 14 33
Clinical stage at baseline, n (%)
N/A 25 53 0.6
B 12 26
C 10 18
Nadir CD4 (cells/mm3), median (IQR) 323 (153, 503) 543 (350, 764) < 0.001 1.002 (1.000–1.004) 0.01
Nadir CD4%, median (IQR) 14.5 (8–21) 21.5 (14–28) < 0.001
Prior history of ART, n (%)
Mono or dual ART 23 19 0.001 0.164 (0.037–0.725) 0.01
Naïve 25 79
cART median (IQR)
Total n˚ of ART regimens 4 (3, 5) 3 (2, 4) 0.2
Total n˚ of cART regimens 2 (2, 3) 3 (2, 4) 0.5
Duration of cART (years) 9.5 (7.4–12) 10.6 (8.2–13.8) 0.1
Baseline CD4 and CD8 median (IQR)
CD4 (cells/mm3) at baseline 563 (201, 1039) 1264 (735, 2299) <0.001 1.000(0.999–1.001) 0.5
CD4% at baseline 20 (8, 28) 32 (20, 38) <0.001
CD8 (cells/mm3) at baseline 1411 (866, 1933) 1375 (861–1964) 0.61
CD8% at baseline 48 (38–60) 35 (22–44) <0.001
CD4/CD8 ratio at baseline 0.4 (0.1, 0.6) 0.9 (0.5, 1.6) <0.001 1.777 (0.782–4.035) 0.1
Viral load median (IQR)
Viral load at baseline (log10) 4.8 (4, 5.4) 4.9 (4.2, 5.7) 0.4
Time of undetectable viral load 9.1 (7.7, 11.4) 9.8 (7.9–12.6) 0.2
https://doi.org/10.1371/journal.pone.0220552.t002
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[14, 15, 16, 21] Moreover, the CD4/CD8 ratio can contribute to the immunological evaluation
of treated patients in a long-term follow-up and may be applied for monitoring both immune
dysfunction and viral reservoir size in virologically suppressed HIV-positive adults. [22]
The median follow-up period of patients on cART in this study was nearly 10 years. To our
knowledge, this study is the largest to date in terms of long term follow-up period on immune
recovery in children. Other studies, however, showed a follow-up period of 5 to 7 years in
naïve children and a follow-up period of 6 years in pre-treated children. [1, 19, 20]
We did not find any association between cART duration or number of regimens and
immune recovery, although was nearly significant (p value was 0.1 and p 0.2 respectively),
probably due to our small sample size. Both groups received a long term therapy with a median
duration of nearly 10 years with various regimens. A longer duration of cART was an indepen-
dent predictor of immune recovery in a study from Thailand. [19] We did not compare the
immune recovery between the different antiretroviral drugs used, but it was described that in
adults, normalization of the CD4/CD8 ratio above a clinically meaningful threshold may be
dependent on the drug class used. [23]
Receiving suboptimal treatment such as mono-dual therapy could lead to an impaired
immune recovery, because these therapies were not efficacy to achieve persistent undetectable
viral load and immune recovery. So initiating cART, after severe immunosuppression has
occurred, is detrimental for the restoration of the CD4 cell count. A third of the patients in our
study had previously received mono or dual therapy and, therefore, achieved a lower CD4/
CD8 ratio at the end of the study compared to naïve patients. Our results are consistent with
those in a study covering a similar population, except that all subjects had previously received
mono or dual therapy where they found a significant association between not reaching
CD4% > 25% during follow-up and the duration of antiretroviral therapy before cART. [1]
A worse immune recovery in our study, while comparing the two groups, was associated
with older age at diagnosis and at cART initiation in univariate analysis. Our interpretation to
this, as reported in previous studies [8, 19, 24, 25, 26], is that early initiation of cART may
improve the immune recovery. However, these associations in our study were not maintained
in multivariate analysis. Data from few studies suggested that the immune recovery is indepen-
dent of the age at cART initiation. [9, 27] Better viral suppression but poorer immunological
responses have been described in older individuals compared to children. [10] The median
time to achieve immunological response (CD4> 30%) has been described to be shorter in chil-
dren younger than two years, irrespective of pre-cART CD4 counts and the time to immune
recovery, and it increased progressively in older children. [25]
Initiation of cART after severe immunosuppression was described as ineffective in several
studies for a normal CD4 count recovery. [1, 11] A study conducted in the United States
showed that children who started ART and who had a higher nadir CD4% were more likely to
achieve a higher CD4%. [8] Two studies conducted in Thailand showed that higher baseline
CD4% was associated with better achievement of immune recovery. [28, 29] These results
show consistency with the ones observed in our cohort, as univariate analysis showed that
patients who had worse immune recovery had a lower CD4 nadir and a lower CD4 count at
baseline, although, only the CD4 nadir remained independently associated to immune recon-
stitution in multivariate analysis. Other studies, have described that patients under greater
immunosuppression had the largest CD4 increase, but only a minority of these patients
achieved CD4> 25%. [20, 24]
So we can say, like in other studies in adults that early initiation, before CD4 decrease, and
effective ART appear to improve CD4/CD8 ratio in long term viral suppression patients. [14]
CDC clinical stage was not associated with immune recovery in our study. In the European
Collaborative Cohort study, children on clinical stage C were less likely to achieve a 20%
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increase in CD4 z-score, compared to those who had cART initiated at clinical stage B or A.
[26] In two studies conducted in Thailand, clinical CDC stage was not an independent predic-
tor for reaching CD4 percentage > 25% after cART initiation. [19, 28]
In our study, higher baseline CD8 counts and lower baseline CD4/CD8 ratio were associ-
ated with worse immune recovery in univariate analysis. Baseline absolute CD8 cell counts
and CD4/CD8 ratio has been described influencing the recovery of CD4/CD8 ratio and CD4
response in HIV-infected adults. [18, 30, 31]
No associations were found between baseline viral load and immune recovery in our popu-
lation, which is consistent with other published data. [19] Longer duration of undetectable
viral load was nearly significant to achieve a CD4/CD8 >1, with p value 0.2, probably due to
the small size of the sample.
Moreover, in our study, ethnicity could not be considered as a predictor for immune
response, as also reported in a study conducted in children in The Netherlands, despite initial
differences in CD4 counts. [32] Similar results were found in adult population, observing a sig-
nificantly lower CD4/CD8 ratio prior to commencing ART in Asian patients compared to
Caucasian, but after adjustment, there was no significant difference between the cohorts in
odds of achieving normal ratio. [33]
A limitation of this study is that, despite being the largest study to date in terms of the
length of follow-up period of patients; in describing the immune reconstitution, the sample
size is not representative of the entire Spanish cohort due to the fact that there were missing
data for most patients in such a long follow-up period and, also due to the observational
nature of the study. The second limitation is that CD4/CD8 ratio is an imperfect measure of
immune reconstitution and immune activation and we did not consider other laboratory
parameters that are now commonly used to describe immune reconstitution (quantification of
CD31+CD45RA+CD4+ T cells) or immune activation (HLADR CD38 expression). The third
limitation is that 30% of children received mono or dual therapy, which implies that these chil-
dren started therapy in an earlier era of treatment when less potent antiretroviral therapy were
available and this potential bias was not addressed.
Conclusion
This study showed the long-term immune recovery after 10 years of initiating and maintaining
suppressive cART, nonetheless one third of patients did not achieve a CD4/CD8 ratio > 1,
being associated with a lower CD4 nadir and receiving previously mono or dual therapy. All
these data suggest that there is a difficulty in achieving immune recovery after severe immune
deterioration, which highlights the importance of an early and effective treatment initiation. In
addition, our observations showed a relationship between incomplete immune recovery and
immune activation, despite maintained undetectable viral load, which requires longer follow
up to elucidate its potential long term consequences.
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